MX9305947A - Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. - Google Patents

Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.

Info

Publication number
MX9305947A
MX9305947A MX9305947A MX9305947A MX9305947A MX 9305947 A MX9305947 A MX 9305947A MX 9305947 A MX9305947 A MX 9305947A MX 9305947 A MX9305947 A MX 9305947A MX 9305947 A MX9305947 A MX 9305947A
Authority
MX
Mexico
Prior art keywords
receptor
procedure
contain
preparation
pharmaceutical compositions
Prior art date
Application number
MX9305947A
Other languages
English (en)
Inventor
Graham Francis Joiner
Francis David King
Laramie Mary Gaster
Paul Adrian Wyman
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220508A external-priority patent/GB9220508D0/en
Priority claimed from GB929221791A external-priority patent/GB9221791D0/en
Priority claimed from GB929221774A external-priority patent/GB9221774D0/en
Priority claimed from GB929223138A external-priority patent/GB9223138D0/en
Priority claimed from GB929223135A external-priority patent/GB9223135D0/en
Priority claimed from GB929224604A external-priority patent/GB9224604D0/en
Priority claimed from GB939309642A external-priority patent/GB9309642D0/en
Priority claimed from GB939311878A external-priority patent/GB9311878D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9305947A publication Critical patent/MX9305947A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen compuestos de la fórmula (I), en donde la fórmula (I) consiste de las fórmulas (I-1) a (I-8), y sales farmecéuticamente aceptables de los mismos, y el uso de un compuesto de la fórmula (I) o una sal farmacéuticamente aceptable del mismo, y su uso como sustancias farmacéuticas en el tratamiento de desórdenes gastrointestinales, desórdenes cardiovasculares y desórdenes del SNC.
MX9305947A 1992-09-29 1993-09-27 Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen. MX9305947A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB929220508A GB9220508D0 (en) 1992-09-29 1992-09-29 Pharmaceuticals
GB929221791A GB9221791D0 (en) 1992-10-16 1992-10-16 Pharmaceuticals
GB929221774A GB9221774D0 (en) 1992-10-16 1992-10-16 Pharmaceuticals
GB929223138A GB9223138D0 (en) 1992-11-05 1992-11-05 Pharmaceuticals
GB929223135A GB9223135D0 (en) 1992-11-05 1992-11-05 Pharmaceuticals
GB929224604A GB9224604D0 (en) 1992-11-24 1992-11-24 Pharmaceuticals
GB939309642A GB9309642D0 (en) 1993-05-11 1993-05-11 Pharmaceuticals
GB939311878A GB9311878D0 (en) 1993-06-09 1993-06-09 Pharmaceuticals

Publications (1)

Publication Number Publication Date
MX9305947A true MX9305947A (es) 1994-06-30

Family

ID=27571305

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9305947A MX9305947A (es) 1992-09-29 1993-09-27 Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.

Country Status (10)

Country Link
US (1) US5696129A (es)
EP (1) EP0662959A1 (es)
JP (1) JPH08502056A (es)
KR (1) KR950703530A (es)
CN (1) CN1092766A (es)
AU (1) AU4830593A (es)
CA (1) CA2145746A1 (es)
MX (1) MX9305947A (es)
NZ (1) NZ256104A (es)
WO (1) WO1994007859A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5726187A (en) * 1992-10-16 1998-03-10 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-HT4 receptor antagonists
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
US6069152A (en) * 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE10143079A1 (de) * 2001-09-03 2003-05-15 Zentaris Ag Cyclische Indol- und Heteroindolderivate, deren Herstellung und Verwendung als Arzneimittel
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
US7291630B2 (en) * 2002-03-28 2007-11-06 Eisai Co., Ltd. Azaindoles as inhibitors of c-Jun N-terminal kinases
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
DE602005005167T2 (de) * 2004-01-29 2009-04-30 Pfizer Inc. 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
BRPI0512046A (pt) 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
MX2007007818A (es) * 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
ES2523851T3 (es) * 2005-03-02 2014-12-02 Theravance Biopharma R&D Ip, Llc Compuestos de quinolinona como agonistas de los receptores 5-HT4

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030051C (en) * 1989-11-17 2001-08-07 Haruhiko Kikuchi Indole derivatives
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
US5260303A (en) * 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
WO1993002677A1 (en) * 1991-08-03 1993-02-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
US5552398A (en) * 1991-09-12 1996-09-03 Smithkline Beecham P.L.C. Azabicyclic compounds as 5-HT4 receptor antagonists
AU2752692A (en) * 1991-10-24 1993-05-21 Smithkline Beecham Plc Imidazopyridines and indolizines as 5-ht4 antagonists
NZ246915A (en) * 1992-02-06 1996-05-28 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives, preparation and pharmaceutical compositions thereof
CA2131797C (en) * 1992-03-12 2010-05-18 Laramie Mary Gaster Condensed indole derivatives as 5ht4-receptor antagonists

Also Published As

Publication number Publication date
EP0662959A1 (en) 1995-07-19
WO1994007859A1 (en) 1994-04-14
US5696129A (en) 1997-12-09
KR950703530A (ko) 1995-09-20
NZ256104A (en) 1996-11-26
CN1092766A (zh) 1994-09-28
JPH08502056A (ja) 1996-03-05
AU4830593A (en) 1994-04-26
CA2145746A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
MX9305947A (es) Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
MX9300616A (es) Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
AR045900A1 (es) Compuesto glucocorticoesteroide, composiciones farmaceuticas que los contienen y su uso para el tratamiento de trastornos inflamatorios y/o alergicos.
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
ES2157314T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
ECSP941122A (es) Derivados de 5-arilindoles
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
GT199200028A (es) Derivados de quinuclidina
MX9700763A (es) Procedimiento para la preparacion de benzoxazoles y derivados de piridinas utiles en el tratamiento de la diabetes del tipo ii, los benzoxazoles y derivados de piridina obtenidos, composiciones de los mismos y su uso.
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
AR047070A1 (es) Derivados de difenilazetidona
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
CO4650038A1 (es) Derivados del indazol sustituidos y compuestos relacionados
MX9306309A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2160648T3 (es) Derivados de piridina.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
MX9301197A (es) Derivados de indol.
ES2096685T3 (es) Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.